Home / Intelligence / Webinars / Part D in Peril: The Inconvenient Math of IRA Part D Redesign
August 14, 2025 | 12:00 - 12:45 PM ET
Two additional sessions will be offered:
August 18 – 12:00 – 12:45 (UTC +8:00) – Asia
August 18 – 12:00 – 12:45 CET – Europe/Berlin
Medicare Part D is undergoing its most significant transformation in decades largely driven by the Inflation Reduction Act (IRA). What does this mean for pharmaceutical manufacturers?
Join us for an engaging discussion with Max Hunt, Partner at Trinity Life Sciences, and special guest Dan Simenc, clinical and actuarial expert at Milliman, as they provide perspectives on recent developments and future expectations for Medicare Part D and Medicare Advantage. The webinar will explore trends in drug spending, the impact of the IRA Part D redesign, learnings from the latest cycle of negotiations and implications for manufacturers.
Whether you’re launching a new therapy or managing an innovative drug, gain the insights you need to stay ahead in the dynamic payer and policy landscape in the U.S.
Key Webinar Topics
- Drug spending trends in 2024 and 2025 to date, including the impact of the IRA Part D redesign
- Learnings from the most recent cycle of manufacturer and Medicare Advantage/Part D negotiations for 2026
- Expectations for access to Medicare Advantage and Part D for innovative drugs and new launches in the next 2-3 years
- Implications for manufacturers of innovative drugs on the market and those that will launch in this period
Featuring
Which session would you like to attend?
Complete the form below to register for the August 14th session at 12:00 PM ET
Complete the form below to register for the August 18th session at 12:00 UTC+8 – Asia
Complete the form below to register for the August 18th session at 12:00 CET – Europe/Berlin
We would contact you in accordance with our Privacy Policy, which we invite you to visit for details about our data privacy practices, including, where appropriate, how you may access and correct the personal data we store or withdraw consent to the collection, use or disclosure of such information. We will not share your email address or personal information. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Blog
Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know
March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences, stakeholders gathered to explore the implications of this new regulatory framework and how to […]
Read More
Blog
Pricing and Access in Germany: Innovation and Strong Evidence Rewarded
Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated drug pricing, incentives for local clinical trials, simplified clinical trial approvals and harmonization of […]
Read More
Blog
Seizing the Storm: Why Pharma Must Plan, Not Panic in Trump’s Second Term
The first 100 days of President Trump’s return to the White House have been anything but ordinary. With a true “Flood the Zone” strategy, there has been a flurry of executive orders, leadership reshuffles, and a re-assertion of executive power, which has signaled the administration is interested in seeing what policy options can “stick.” While […]
Read More